Literature DB >> 26072726

Management of iatrogenic subclavian artery pseudoaneurysms.

Chris Klonaris1, George Kouvelos2, Mikes Doulaptsis1, Athanasios Katsargyris3, Achilleas Chatziioannou4.   

Abstract

BACKGROUND: To report our experience in the management of iatrogenic subclavian artery pseudoaneurysms (SAPs).
METHODS: During a 6-year period, 5 patients were treated urgently for SAP.
RESULTS: Two patients presented with rupture, 2 with dyspnea, whereas 1 had unremitting severe pain. Three patients underwent preoperative computed tomography angiography and 2 digital subtraction angiography. Three patients were treated with an open surgical procedure, whereas 2 were managed by endovascular means. A combined supraclavicular and/or infraclavicular approach was used in 2 patients, whereas a midsternotomy was mandatory to achieve proximal control in one. A combined transfemoral and/or brachial approach was used in both patients treated endovascular. No perioperative deaths or procedure-related complications occurred. All symptoms were relieved, whereas the median hospital stay was 8 days. During a mean follow-up period of 20.4 ± 10 months, none of the patients needed any reintervention.
CONCLUSIONS: Iatrogenic SAPs constitute a clinical entity that may need surgical treatment, especially in the presence of symptoms. In relatively stable patients with no major compression issues, stenting could be considered as an adequate therapy for these situations. Open surgical repair should be considered when there is significant compression of adjacent structures or failure of the endovascular approach.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26072726     DOI: 10.1016/j.avsg.2015.03.047

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  1 in total

1.  Thoracoacromial artery injury after tube thoracostomy for pneumothorax.

Authors:  Shravan Leonard-Murali; Adhnan Mohamed; Ann Woodward; Dionne Blyden
Journal:  BMJ Case Rep       Date:  2020-08-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.